Proteostasis Therapeutics (PTI) PT Raised to $8.00

Proteostasis Therapeutics (NASDAQ:PTI) had its price target hoisted by investment analysts at Leerink Swann from $6.00 to $8.00 in a report released on Tuesday. Leerink Swann’s target price would indicate a potential upside of 46.25% from the stock’s current price. Leerink Swann also issued estimates for Proteostasis Therapeutics’ Q1 2018 earnings at ($0.49) EPS, Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.46) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.89) EPS, FY2019 earnings at ($1.52) EPS and FY2020 earnings at ($1.57) EPS.

PTI has been the subject of a number of other reports. Robert W. Baird boosted their price objective on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.

Shares of Proteostasis Therapeutics (NASDAQ:PTI) traded down $0.67 during midday trading on Tuesday, reaching $5.47. 4,317,800 shares of the company were exchanged, compared to its average volume of 316,455. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. analysts anticipate that Proteostasis Therapeutics will post -2.47 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. LMR Partners LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $127,000. Goldman Sachs Group Inc. grew its position in Proteostasis Therapeutics by 364.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock worth $243,000 after purchasing an additional 40,731 shares during the period. Susquehanna International Group LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $254,000. Dimensional Fund Advisors LP bought a new stake in Proteostasis Therapeutics in the 2nd quarter worth approximately $296,000. Finally, Sabby Management LLC grew its position in Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock worth $586,000 after purchasing an additional 65,451 shares during the period. 68.08% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/14/proteostasis-therapeutics-pti-pt-raised-to-8-00.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit